Drug Profile
Research programme: pain therapeutics - St. Charles Pharmaceuticals
Alternative Names: SCP-123Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator St. Charles Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (IV)
- 12 Dec 2005 Preclinical trials in Pain in USA (IV)